Chang Lixian, Cui Zejia, Shi Deyang, Chu Yajing, Wang Bichen, Wan Yang, Ma Qiuyi, Zhang Ranran, Li Haoyuan, Cheng Xuelian, Cheng Tao, Zhu Xiaofan, Li Cheng, Yuan Weiping
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Joint Graduate Program of Peking-Tsinghua-NIBS, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Exp Hematol Oncol. 2022 Sep 27;11(1):64. doi: 10.1186/s40164-022-00319-5.
Fanconi anemia (FA) is a rare disease of bone marrow failure. FA patients are prone to develop myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, the molecular clonal evolution of the progression from FA to MDS/AML remains elusive.
Herein, we performed a comprehensive genomic analysis using an FA patient (P1001) sample that transformed to MDS and subsequently AML, together with other three FA patient samples at the MDS stage.
Our finding showed the existence of polyclonal pattern in these cases at MDS stage. The clonal evolution analysis of FA case (P1001) showed the mutations of UBASH3A, SF3B1, RUNX1 and ASXL1 gradually appeared at the later stage of MDS, while the IDH2 alteration become the dominant clone at the leukemia stage. Moreover, single-cell sequencing analyses further demonstrated a polyclonal pattern was present at either MDS or AML stages, whereas IDH2 mutated cell clones appeared only at the leukemia stage.
We thus propose a clonal evolution model from FA to MDS and AML for this patient. The results of our study on the clonal evolution and mutated genes of the progression of FA to AML are conducive to understanding the progression of the disease that still perplexes us.
范可尼贫血(FA)是一种罕见的骨髓衰竭疾病。FA患者易于发展为骨髓增生异常综合征(MDS)和急性髓系白血病(AML)。然而,从FA进展到MDS/AML的分子克隆进化仍不清楚。
在此,我们使用了一份从FA转变为MDS并随后发展为AML的患者(P1001)样本,以及其他三份处于MDS阶段的FA患者样本进行了全面的基因组分析。
我们的研究结果表明,这些处于MDS阶段的病例存在多克隆模式。对FA病例(P1001)的克隆进化分析显示,UBASH3A、SF3B1、RUNX1和ASXL1的突变在MDS后期逐渐出现,而IDH2改变在白血病阶段成为优势克隆。此外,单细胞测序分析进一步证明,在MDS或AML阶段均存在多克隆模式,而IDH2突变细胞克隆仅出现在白血病阶段。
因此,我们为该患者提出了一个从FA到MDS再到AML的克隆进化模型。我们对FA进展为AML的克隆进化和突变基因的研究结果有助于理解这一仍困扰我们的疾病进展过程。